EUVIMEDEUVIMED entdecken
Kohortenstudie

Comparison of secukinumab effectiveness in treating psoriatic lesions in patients with psoriasis alone and concomitant psoriatic arthritis: A retrospective longitudinal cohort study

Jingge Xiao, Jiashuai Li, Chang Honghong, Guo Zhou, Junchen Chen, Wu Zhu, Yehong Kuang

Indian Journal of Dermatology, Venereology and Leprology · 04.07.2026 · 92 · 710-715

DOI: 10.25259/ijdvl_29_2025 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 04.07.2026. Verfasst von Jingge Xiao und 6 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secukinumab, an interleukin-17A inhibitor, has been widely used to treat psoriasis (PsO) and psoriatic arthritis (PsA). However, it remains unclear whether psoriasis patients with PsA achieve comparable effectiveness to those with psoriasis alone.

Objective

To compare secukinumab's effectiveness in treating psoriatic lesions in psoriasis patients and those with concomitant PsA and to analyse the disparities.

Methods

A retrospective longitudinal cohort study was conducted on patients treated with secukinumab for PsO and PsA between June 1, 2020 and December 1, 2022. Psoriasis area and severity index (PASI) scores were assessed at weeks 0, 4, 12, 24 and 48. The achievement of PASI 75, PASI 90 and PASI 100 were assessed between the PsO and PsA group with logistic generalised estimating equations using a logit link. Propensity score matching was used for sensitivity analysis.

Results

336 psoriatic patients were enrolled, of whom 41 had PsA as well. After adjustment, patients with PsA demonstrated comparable PASI 75/90/100 responses at week 4 but significantly inferior outcomes at weeks 12, 24 and 48 compared to those with psoriasis alone. The treatment disparity in PASI 75 achievement emerged at week 12 (94.9% vs 82.5% odds ratio (OR) 0.264, 95% confidence interval (CI) 0.098-0.711, p =0.008); it was most pronounced at week 48 (95.0% vs 73.3% OR 0.139, 95% CI 0.054-0.356, p

Zitieren

APA

Xiao, J., Li, J., Honghong, C., Zhou, G., Chen, J., Zhu, W., & Kuang, Y. (2026). Comparison of secukinumab effectiveness in treating psoriatic lesions in patients with psoriasis alone and concomitant psoriatic arthritis: A retrospective longitudinal cohort study. Indian Journal of Dermatology, Venereology and Leprology, 92, 710-715. https://doi.org/10.25259/ijdvl_29_2025

Vancouver

Xiao J, Li J, Honghong C, Zhou G, Chen J, Zhu W, et al. Comparison of secukinumab effectiveness in treating psoriatic lesions in patients with psoriasis alone and concomitant psoriatic arthritis: A retrospective longitudinal cohort study. Indian Journal of Dermatology, Venereology and Leprology. 2026;92:710-715. doi:10.25259/ijdvl_29_2025

BibTeX
@article{Xiao2026,
  author = {Xiao, Jingge and Li, Jiashuai and Honghong, Chang and Zhou, Guo and Chen, Junchen and Zhu, Wu and Kuang, Yehong},
  title = {Comparison of secukinumab effectiveness in treating psoriatic lesions in patients with psoriasis alone and concomitant psoriatic arthritis: A retrospective longitudinal cohort study},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2026},
  volume = {92},
  pages = {710--715},
  doi = {10.25259/ijdvl_29_2025}
}
Kostenlos starten →